NASDAQ · KLACHealthcareOptical Instruments

KLA financials

$196.53+3.89%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ4 '26
Jun 30
Q3 '26
Mar 31
Q2 '26
Dec 31
Q1 '26
Sep 30
Q4 '25
Jun 30
Q3 '25
Mar 31
Q2 '25
Dec 31
Q1 '25
Sep 30
Q4 '24
Jun 30
Q3 '24
Mar 31
Q2 '24
Dec 31
Q1 '24
Sep 30
Revenue$3.66B$3.42B$3.30B$3.21B$3.17B$3.06B$3.08B$2.84B$2.57B$2.36B$2.49B$2.40B
Gross profit$2.24B$2.09B$2.03B$1.97B$1.97B$1.89B$1.86B$1.69B$1.56B$1.37B$1.51B$1.45B
Gross margin61.4%61.1%61.4%61.3%62.0%61.6%60.3%59.6%60.7%57.9%60.7%60.5%
Operating income$1.55B$1.41B$1.36B$1.34B$1.35B$1.30B$1.00B$1.12B$977.3M$736.4M$733.3M$899.2M
Net income$1.36B$1.20B$1.15B$1.12B$1.20B$1.09B$824.5M$945.9M$836.4M$601.5M$582.5M$741.4M
Net margin37.3%35.2%34.7%34.9%37.9%35.5%26.8%33.3%32.6%25.5%23.4%30.9%
Diluted EPS$0.28$0.91$0.87$0.85$0.24$0.82$0.62$0.70$0.62$0.44$0.43$0.54
EBITDA$1.65B$1.51B$1.46B$1.43B$1.45B$1.40B$1.35B$1.22B$977.3M$906.1M$1.05B$1.00B
Operating cash flow$906.4M$707.5M$1.37B$1.16B$1.16B$1.07B$849.5M$995.2M$892.6M$910.0M$622.2M$883.7M
Free cash flow$817.1M$622.3M$1.26B$1.07B$1.06B$990.0M$757.2M$934.8M$831.9M$838.2M$545.4M$815.7M
Diluted shares4,882.4M1,317.5M1,320.1M1,323.8M4,947.9M1,333.0M1,339.3M1,348.6M5,038.3M1,358.6M1,362.5M1,371.0M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$1.65B$1.79B$2.45B$1.95B$2.08B$1.86B
Short-term investments$3.25B$3.17B$2.76B$2.74B$2.42B$2.17B
Total debt$5.89B$5.89B$5.89B$5.89B$5.88B$5.88B
Total assets$17.95B$16.87B$16.72B$16.32B$16.07B$15.19B
Total liabilities$11.60B$11.04B$11.25B$11.33B$11.38B$11.18B
Shareholders' equity$6.35B$5.83B$5.47B$4.99B$4.69B$4.00B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology